TY  - JOUR
AU  - Vaquero-Siguero, Nuria
AU  - Mu, Quanhua
AU  - Kroon, Paula
AU  - Zhang, Ying
AU  - Galán-Ganga, Marcos
AU  - Bao, Zhaoshi
AU  - Wang, Zheng
AU  - Liu, Hanjie
AU  - Zhao, Junfei
AU  - Kim, Hoon
AU  - Rodriguez-Perales, Sandra
AU  - Nam, Do-Hyun
AU  - Verhaak, Roel G W
AU  - Rabadan, Raul
AU  - Jiang, Tao
AU  - Wang, Jiguang
AU  - Oldrini, Barbara
AU  - Squatrito, Massimo
AU  - Sa, Jason K
AU  - Verhaak, Roel G. W.
PY  - 2020
DO  - 10.1038/s41467-020-17717-0
UR  - http://hdl.handle.net/20.500.12105/10958
AB  - Temozolomide (TMZ) is an oral alkylating agent used for the treatment of glioblastoma and is now becoming a chemotherapeutic option in patients diagnosed with high-risk low-grade gliomas. The O-6-methylguanine-DNA methyltransferase (MGMT) is...
LA  - eng
PB  - Nature Publishing Group
KW  - PROMOTER METHYLATION
KW  - RNA-SEQ
KW  - GLIOBLASTOMA
KW  - TEMOZOLOMIDE
KW  - GENE
KW  - BENEFIT
TI  - MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas.
TY  - journal article
ER  -